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Abstract
Background: X-linked Duchenne muscular dystrophy (DMD), the most frequent human hereditary skeletal muscle
myopathy, inevitably leads to progressive dilated cardiomyopathy. We assessed the effect and safety of a combined
treatment with the ACE-inhibitor enalapril and the β-blocker metoprolol in a German cohort of infantile and juvenile
DMD patients with preserved left ventricular function.
Methods Trial design: Sixteen weeks single-arm open run-in therapy with enalapril and metoprolol followed by a
two-arm 1:1 randomized double-blind placebo-controlled treatment in a multicenter setting. Inclusion criteria: DMD
boys aged 10–14 years with left ventricular fractional shortening [LV-FS]≥ 30% in echocardiography. Primary endpoint:
time from randomization to first occurrence of LV-FS < 28%. Secondary: changes of a) LV-FS from baseline, b) blood
pressure, c), heart rate and autonomic function in ECG and Holter-ECG, e) cardiac biomarkers and neurohumeral serum
parameters, f) quality of life, and g) adverse events.
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Results: From 3/2010 to 12/2013, 38 patients from 10 sites were centrally randomized after run-in, with 21 patients
continuing enalapril and metoprolol medication and 17 patients receiving placebo. Until end of study 12/2015, LV-FS
< 28% was reached in 6/21 versus 7/17 patients. Cox regression adjusted for LV-FS after run-in showed a statistically
non-significant benefit for medication over placebo (hazard ratio: 0.38; 95% confidence interval: 0.12 to 1.22; p = 0.10).
Analysis of secondary outcome measures revealed a time-dependent deterioration of LV-FS with no statistically
significant differences between the two study arms. Blood pressure, maximal heart rate and mean-NN values were
significantly lower at the end of open run-in treatment compared to baseline. Outcome analysis 19months after
randomization displayed significantly lower maximum heart rate and higher noradrenalin and renin values in the
intervention group. No difference between treatments was seen for quality of life. As a single, yet important adverse
event, the reversible deterioration of walking abilities of one DMD patient during the run-in period was observed.
Conclusions: Our analysis of enalapril and metoprolol treatment in DMD patients with preserved left ventricular
function is suggestive to delay the progression of the intrinsic cardiomyopathy to left ventricular failure, but did not
reach statistical significance, probably due to insufficient sample size.
Clinical trial registration: DRKS-number 00000115, EudraCT-number 2009–009871-36.
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Background
Mutations of the human dystrophin gene on chromosome
Xp21 cause Duchenne muscular dystrophy (DMD) [1],
which is the most frequently occurring muscular dys-
trophy in humans with an incidence of 1 in 3600–6000
male births [2]. In addition to early onset and progressive
muscular weakness and wasting, which inevitably leads to
loss of ambulation of boys between 9 and 13 years of age
[3], nearly all DMD patients develop dilated cardiomyop-
athy with impaired systolic function in their second dec-
ade of life [4–8]. Although promising therapeutic options
such as ataluren for stop codon read-through are available
for eligible (< 10%) of the patients [9], to date, no curative
therapy is available for DMD. Though multidisciplinary
care, comprising early treatment with corticosteroids,
physiotherapy, early antibiotic treatment of pulmonary
chest infections, scoliosis surgery with insertion of spinal
rods, implementation of respiratory support and drug
treatment of heart failure, has substantially improved life
expectancy and quality of life for DMD patients, most
patients die in the second to the fourth decade of life due
to combined respiratory and cardiac failure [2, 4, 10, 11].
Thus, regular cardiological and pulmonary diagnostic
work-up of all DMD patients is mandatory to assess indi-
vidual heart and respiratory function and to adapt thera-
peutic strategies [12].
In general, the medical treatment of cardiomyopathy
in pediatric patients is still an open debate [13]. While
evidence based studies and guidelines providing treat-
ment recommendations for adult cardiomyopathy with
impaired left ventricular function, including the use of
the angiotensin converting enzyme inhibitor enalapril
and the beta receptor blocker metoprolol [14, 15] exists,
corresponding data for pediatric patients is vastly lack-
ing. Thus, the rationale for the use of most heart failure
medications in pediatric patients is mostly extrapolated
from studies in adult heart failure [16]. In the context of
DMD a number of open studies indicated that ACE in-
hibitors, angiotensin receptor blockers, beta-blockers
and/or aldosterone antagonists might improve or pre-
serve left ventricular systolic function and may delay the
progression of cardiomyopathy [4, 17–21]. Moreover,
one study demonstrated that the early intervention with
perindopril led to a significantly higher overall survival
in DMD patients with preserved left ventricular ejection
fraction at baseline [18]. Though the comparison and
interpretation of the later studies is generally hampered
by their individual methodological design and the use of
different outcome measurements [19], the available data
supports the use of heart failure medication in DMD
patients but provides no conclusive evidence regarding
the optimal timing of therapy initiation [4, 19, 21, 22].
In the present multicenter study we assessed the
effects of a combined therapy of the angiotensin con-
verting enzyme inhibitor enalapril and the β-receptor
blocker metoprolol on the onset of significant left ven-
tricular dysfunction in 10–14 year old DMD boys with
preserved left ventricular function.
Methods
Patients
Patients for this investigator-initiated, double-blind,
randomized, placebo-controlled multicenter study were re-
cruited at 10 German study sites (Berlin, Dresden, Erlangen,
Essen, Freiburg, Giessen, Göttingen, Heidelberg, Munich,
Oldenburg) from March, 2010 to December, 2013. Inclu-
sion criteria for boys suffering from Duchenne muscular
dystrophy were: 1) the diagnosis was based on a genetically
confirmed disease causing mutation or report of negative
dystrophin immunostaining in a diagnostic muscle biopsy,
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2) age of 10 to 14 years, 3) preserved left ventricular func-
tion as defined by echocardiography with left ventricular
fractional shortening ≥30% in the long-axis motion-mode,
4) normal renal function with glomerular filtration rate >
30ml/min/1.73m2, and 5) ability to participate in the
assessment of primary and secondary outcome measures.
Exclusion criteria were i) any contraindication for treatment
with angiotensin converting enzyme inhibitors or β-
blockers, ii) previous treatment with those drugs in the past
three months, iii) abnormal liver function defined by eleva-
tion (≥2x) of gamma-glutamyltranspeptidase and bilirubine,
iv) left ventricular dilation above the 97th percentile as de-
fined by echocardiography in the long-axis motion-mode,
and v) participation in other clinical trials. This clinical trial
was approved by the regulatory authorities and ethics com-
mittees at each study site and performed in accordance
with good clinical practice guidelines. The objectives, study
design, risks, and benefits of participation were explained to
all participants, and written informed consent was obtained
from patients and parents before enrolment.
Open run-in, randomization and masking
The principle of anti-congestive medications requires
up-titration of dosages to the individually maximum tol-
erated level within a safety range [14, 15]. To define the
individual drug tolerance in all of the patients screened
for eligibility in this study, we opted for a preceding 16
weeks open run-in period with enalapril (enalapril-ma-
leat) and metoprolol (metoprolol-succinat). Drug dos-
ages of enalapril and metoprolol were increased step-by-
step in 3 weight classes in 4 timely shifted steps for each
of the drugs up to the maximum final daily dosage of 10
mg enalapril / 47.5mg metoprolol (patient weight < 45 kg),
10mg enalapril / 71.25mg metoprolol (patient weight 45 -
< 60 kg) and 20mg enalapril / 95mg metoprolol for pa-
tients with a body weight > 60 kg. After 16 weeks open
run-in period, patients were randomly assigned at a 1:1
ratio to receive either the combination of enalapril and
metoprolol without interruption or placebo with a 4 weeks
stepwise wash-out protocol to disguise potential rebound
effects in the placebo group. A stratified block randomiza-
tion with randomly varying block sizes of two or six partici-
pants and stratification for trial site was used. Allocation of
patients was performed centrally by the pharmacy of the
University Hospital Erlangen based on computer-generated
lists. Both active drugs and placebo were supplied by Hexal
AG (Holzkirchen, Germany) as identically appearing tab-
lets. Active drugs and placebo were identically prepacked to
maintain the masking for the patient and investigator by
the certified pharmacy of the University Hospital Erlangen
according to good manufacturing practice for pharmaceuti-
cals. Dose levels of study medication were generally kept
constant but adapted to changes in body weight classes.
The use of steroids or a history of the use of steroids was
recorded at baseline. During the study period start of ster-
oid therapy was not permissible but occurred in single in-
stances. Patients who had reached the primary endpoint or
the end of the study received 4 weeks of blinded wash-out
medication. Thereafter, guideline-conform treatment was at
the investigator’s discretion.
Outcome measures
The primary outcome was the time from randomization
to the first occurrence of a left ventricular fractional
shortening < 28% in the long-axis motion-mode of echo-
cardiography. Corresponding analyses were performed
biannually at the individual study sites. Visits continued
to end of study after the primary endpoint was reached.
Secondary outcome measurements were 1) echocardio-
graphic changes of left ventricular fractional shortening
from the end of the run-in period, 2) echocardiographic
changes of left ventricular diastolic diameter and systolic
ventricular septum thickness measurements by motion-
mode, 3) echocardiographic tissue-Doppler analyses (see
below), 4) blood pressure values, 5) electrocardiograms and
Holter-electrocardiograms (see below), 6) laboratory tests
(see below), 7) quality of life rating (see below), and 8) ad-
verse events.
Tissue Doppler data comprised assessment of septal, left
ventricular and right ventricular longitudinal function by
analysis of systolic strain in the basal, mid and apical region,
respectively. Recording of tissue-Doppler data was
restricted to the availability of a GE-echo-machine at the
study site. All echocardiographic and tissue-Doppler data
were collected in a standardized way in four-chamber-view
as established by the German competence network for
Congenital Heart Disease (http://www.kinderkardiologie.
org/fileadmin/user_upload/Stellungnahmen/Qualitaetsstan-
dardsEcho.pdf). Tissue Doppler data were centrally ana-
lyzed by the same investigator in the tissue Doppler
reference center of the German competence network for
Congenital Heart Disease in Freiburg.
Electrocardiograms and Holter-electrocardiograms were
centrally analyzed by a blinded investigator in Erlangen.
Holter-ECG analyses included heart frequency analyses
and heart rate variability measures (mean NN: average
normal R to R interval; SDNN: Standard deviation of R to
R intervals; SDANN: Standard deviation of the means for
each R to R segment; ASDNN: average standard deviation
of all 5-min R to R- intervals; rMSSD: Root-mean-Square
of successive differences of NN [normal R to R intervals];
pNN50: fraction of NN intervals that differ by more than
50ms from the previous NN interval).
Laboratory tests comprised the neurohumoral markers
renin, angiotensin II, aldosterone and norepinephrine
and the biomarker NT-pro-BNP.
The German Kiddo-KINDL questionnaire for adoles-
cents aged 12–16 years [23] was used as a generic quality
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of life rating measure. According to the study protocol,
quality of life-questionnaire was first requested at the
screening visit. A complete survey of all patients was re-
peated one year after randomization and then annually.
The safety of enalapril and metoprolol administration
was monitored from the run-in period until 30 days after
discontinuation of the study drugs by adverse event re-
ports and biannual physical examination, assessment of
blood pressure, and local safety laboratory tests (including
creatinine, potassium, sodium, urea, glutamate oxalacetate
transaminase [GOT], glutamate pyruvate transaminase
[GPT], γ-glutamyl transpeptidase [γ-GT] and bilirubin).
As serum creatinine titer is not a reliable biomarker for
renal function in patients with Duchenne muscular dys-
trophy because of their low muscle mass [24], cystatin C
was measured when creatinine titers were elevated. Safety
laboratory values were directly assessed by local investiga-
tors. Abnormal values considered to yield clinical signifi-
cance were reported as adverse events.
Statistical analysis
Initially, the target was 130 patients randomized within
three years, plus three years additional follow-up, due to
feasibility constraints. We anticipated that 50% of patients
on placebo would suffer from an LV-FS < 28% after 4 years
of individual follow-up7. With a cumulative drop-out rate
of 5% up to year 4.5 (median follow-up time), a log-rank
test with two-sided significance level 5% of time from
randomization to first occurrence of LV-FS < 28% would
have 80% power if the hazard ratio for enalapril and meto-
prolol versus placebo was 0.46 (Lakatos approximation, 58
events required), corresponding to an improvement to
72.7% free of left-ventricular dysfunction (LV-FS < 28%)
after 4 years. Given previous results [17], a hazard ratio of
0.46 seemed achievable, but smaller treatment benefits
would also be clinically relevant. Due to difficulties in re-
cruitment, the target number was reduced to 55 patients
in December 2012. This would still yield 80% power to de-
tect a difference between treatments with respect to
change in LV-FS from end of run-in to the visit scheduled
19months after randomization (visit 4), which was consid-
ered the most relevant secondary outcome. Assuming a
standard deviation of 4% at visit 4 [17], a t-test with
two-sided significance level 5% would achieve this power
if the mean difference 19months after randomization was
3.1%. By December 2013, 42 patients had given informed
consent, and it was decided to stop recruitment and con-
tinue follow-up until end of December 2015.
The analysis of treatment effects was done by intention-
to-treat in all 38 patients who were randomized after the
run-in period. In the primary analysis, time from
randomization to first occurrence of an LV-FS < 28% was
analyzed with the proportional hazards model, censoring at
the last visit for those patients in whom no LV-FS < 28%
was observed. The treatment effect was tested using the
Wald-test at two-sided significance level of 5%, and was es-
timated as a hazard ratio with two-sided 95% confidence
interval. Due to the insufficient recruitment, covariate ad-
justment for study site originally planned in the study
protocol was replaced by adjustment for LV-FS measured
after run-in in the statistical analysis plan before the blind
was broken. A planned sensitivity analysis to explore a
possible confounding effect of concomitant treatment with
steroids was done by additional inclusion treatment with
steroids as a time-dependent covariate in the primary
proportional hazards model.
Secondary efficacy outcomes were analyzed in a mixed
model for repeated measures including outcomes after
randomization and 19months later as endpoints and
outcome after run-in, treatment, and the interaction be-
tween measurement time and treatment as covariates;
subjects were modelled as random effects. Linear regres-
sion originally planned in the protocol was replaced by
this longitudinal model in the statistical analysis plan to
allow inclusion of all randomized patients under a miss-
ing at random assumption even if they dropped out after
randomization. Changes from screening to end of run-in
were summarized by means with 95% confidence inter-
vals. Entries to the KINDL questionnaires were evalu-
ated in accordance with the corresponding manual.
Adverse events were coded by the Medical dictionary for
regulatory activities (MedDRA version 19.1) and summa-
rized single-armed (verum) for those events with onset
from run-in to four weeks after randomization,
two-armed (verum versus placebo) for those events with
onset after that, restricting the analysis sets to those pa-
tients who received at least one dose of study medication
in the corresponding period.
All p-values were two-sided and considered explora-
tory except for the primary analysis, programming was
done with SAS (version 9.2) in UNIX. An independent
data monitoring committee reviewed safety data on a
yearly basis. An interim analysis of efficacy data, which
had been planned initially, was cancelled because of the
reduced target number of patients.
Results
Study population
Between March 2010 and December 2013, 42 boys gave
informed consent, 41 started open run-in medication
and 38 patients were randomized after a run-in (Fig. 1).
The study was concluded with the last patient visit in
December 2015.
Outcome after open run-in phase (all patients)
During the open run-in medication period, two protocol
deviations were noted: in one patient the run-in had to
be repeated (due to a bone fracture) and was delayed in
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a second patient. Three of 41 patients dropped out of
the study due to discontinuation of study medication:
one patient withdrew consent because of increased hair
loss, a second patient after an episode of febrile
infection, nausea and vomiting, and in a third patient
the local investigator stopped the medication because of
decreasing walking abilities which completely recovered
after disposing of the drugs. In the remaining 38 patients
the maximum dose level was tolerated in 29 patients
(76%), whereas 9 patients (24%) tolerated only reduced
medication levels (Table 1).
We observed statistically significant changes with a drop
of systolic blood pressure, a shortening of QTc-time (ECG),
a drop of heart rate (ECG and Holter-ECG) and of heart
rate variability (Holter-ECG) (Table 1, and Additional file 1:
Table S1A). All patients displayed sinus rhythm. Changes in
ECG pattern indicating a right ventricular hypertrophy
occurred in 1 out of 38 patients during run-in. Short epi-
sodes of ventricular tachycardia were documented in 2 out
of 38 patients at screening, but were not found in any pa-
tient under medication (Additional file 1: Table S1A).
The observed changes of left ventricular fractional
shortening were marginal and without statistical signifi-
cance: 35 ± 4% (mean ± SD) at screening and 36 ± 4%
(mean change 0.4, 95% CI -1.1 to 1.9, p = 0.58) in the 38
randomized patients after up-titration of the drugs
(Table 1). There were no statistically significant changes
in other echocardiographic measurements and in Tissue
Doppler analysis (Additional file 1: Table S1A).
Changes of safety laboratory testings were marginal
(Additional file 1: Table S1A) and none of the safety la-
boratory testings was reported as an adverse event (AE).
According to the study protocol, quality of life-question-
naire was first requested at the screening visit and complete
Fig. 1 CONSORT Diagram. 1) In 2 versus 3 patients (Enalapril & Metoprolol versus Placebo), intake terminated prematurely (multiple reasons could
apply): 5x patient wish (2 versus 3), 3x withdrawal of consent (1 versus 2), 1x patient non-compliance (1 versus 0), and one adverse event (0
versus 1: loss of appetite, increased feeling of thirst)
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survey of all patients was repeated one year after
randomization. The overall quality of life score was 73.5 ±
10.0 (n = 42) and 73.3 ± 11.3 (n = 35), respectively.
Adverse events (AEs) with onset from run-in to four
weeks after randomization were reported in 37 out of 41
patients (90%) and are listed according to MedDRA® pre-
ferred terms in Table 2 only if more than one event of the
same kind was documented. Incidence of AE reports was
0.7 per person-month (142 AEs/201 person-months). One
AE (muscular weakness) induced stop of medication.
Baseline measurements before randomization
After run-in, 38 patients were randomized across 10
sites (Fig. 1). 21 were randomly assigned to continue ac-
tive medication at the dose level achieved during run-in
(enalapril and metoprolol). 17 patients were assigned to
receive placebo after a four weeks blinded wash-out
phase (placebo). Baseline characteristics of the patients
by randomized treatment are given in Table 3. At the
point of randomization, baseline heart rate (ECG and
Holter-ECG) as well as heart rat variability values such
as mean NN were unequally distributed among the enal-
april and metoprolol and the placebo group. Patients
randomized to placebo treatment had higher heart rates
and larger mean NN-values (Table 3).
Outcome after randomization
Patient follow-up for the primary endpoint included 108
person-years, and study visits took place until end of
study in 29 of 38 patients. Three versus 6 patients (Enal-
april and metoprolol versus placebo) discontinued study
visits prematurely, thereof 1 versus 3 patients after they
had reached the primary endpoint (Fig. 1).
Results-efficacy-primary
After randomization, a LV-FS < 28% was observed in 6 of
21 and 7 of 17 patients assigned to Enalapril and Metopro-
lol versus placebo, respectively. For the primary endpoint,
time from randomization to the first occurrence of LV-FS
< 28%, Cox regression adjusted for LV-FS after run-in
showed a statistically non-significant benefit for enalapril
and metoprolol over placebo (hazard ratio [HR] 0.38; 95%
confidence interval [CI] 0.12 to 1.22; p = 0.10) (Fig. 2).
Left ventricular fractional shortening after run-in had
a significant impact on time to left ventricular fractional
shortening < 28%: Each percent point after run-in
Table 1 Outcomes before and after run-in medication (all patients)
Screening1) End of run-in1) Change from screening to end of run-in2)
Dose level after run-in
maximum dose – – 76% 29/38 – –
step 3 dose – – 18% 7/38 – –
step 2 dose – – 5% 2/38 – –
Systolic blood pressure [mmHg] 111 ± 13 n = 41 102 ± 14 n = 38 −9 [−13 to −5]* n = 37
Echocardiography
Left ventricle fractional shortening [%] 35 ± 3 n = 42 36 ± 4 n = 38 0 [−1 to 2] n = 38
Electrocardiogram (ECG)
Ventricular heart rate [beats/min] 97 ± 14 n = 41 88 ± 16 n = 38 −9 [−13 to −4]* n = 37
Holter-Electrocardiogram (Holter-ECG)
Ventricular heart rate [beats/min]:
minimum 73 ± 10 n = 38 69 ± 11 n = 35 −2 [−6 to 2] n = 34
maximum 140 ± 15 n = 38 129 ± 15 n = 35 −11 [−16 to −6]* n = 34
mean 101 ± 13 n = 38 93 ± 11 n = 35 −8 [−13 to −3]* n = 34
Heart rate variability (Holter ECG)
mean NN [ms] 574 ± 122 n = 23 627 ± 140 n = 21 52 [24 to 81]* n = 19
SDNN [ms] 85 ± 23 n = 22 97 ± 29 n = 21 12 [3 to 21]* n = 19
SDANN [ms] 69 ± 24 n = 23 73 ± 24 n = 21 0 [−12 to 13] n = 20
ASDNN [ms] 45 ± 18 n = 22 57 ± 21 n = 21 11 [5 to 18]* n = 19
rMSSD [ms] 35 ± 18 n = 24 46 ± 23 n = 22 9 [−1 to 18] n = 21
pNN50 [%] 9 ± 8 n = 24 15 ± 13 n = 21 5 [1 to 10]* n = 20
* difference is statistically significant
1) Data are %, x/n or mean ± SD, n
2) Data are mean change [95% confidence interval], n
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lowered the hazard of left ventricular dysfunction by a
factor (HR) of 0.72 (95%CI 0.55 to 0.93, p = 0.011).
Concomitant steroid treatment was given at least once
after randomization in 10 of 21 patients on enalapril and
metoprolol versus 11 of 17 patients on placebo. Sensitiv-
ity analysis to investigate a potential confounding impact
by inclusion of a time-dependent indicator of steroid in-
take did not alter the estimated effect of enalapril and
metoprolol versus placebo (HR 0.32; 95% CI 0.09 to
1.13; p = 0.076). The effect of steroid intake on time to
first occurrence of LV-FS < 28% was estimated as a HR
of 0.61 (95%CI 0.16 to 2.37; p = 0.47).
Results-efficacy-secondary
Change of left ventricular fractional shortening was con-
sidered the most relevant secondary efficacy endpoint.
The difference between treatments at month 19, esti-
mated as 0.62% in favor of enalapril and metoprolol
(Table 4), was not statistically significant (95%CI − 1.98
to 3.22%, p = 0.63). Adjusted analysis for LV-FS after
run-in showed that LV-FS decreased by − 0.10% per
month in the enalapril and metoprolol -group (95%CI −
0.21 to 0.02%, p = 0.10) compared to − 0.13% per month
with placebo (95%CI − 0.25 to 0.00%, p = 0.042). We ob-
served no effect on left ventricular diameter or ventricu-
lar thickness (Table 4).
Adjusted differences between treatments were not sta-
tistically significant for systolic blood pressure (Table 4).
All patients had sinus rhythm during whole study
period. No episodes of supraventricular or ventricular
tachycardias had been registered in any Holter-ECG
recordings.
Baseline distribution of heart frequencies after run-in
in ECG and Holter-ECG was asymmetric (Table 3). Ad-
justed differences showed significantly lower maximal
ventricular heart rate in Holter-ECG in the enalapril and
metoprolol group compared to placebo (Table 4).
Changes of heart rate variability parameters were sta-
tistically significant as analyzed for all patients during
open run-in medication for an increase of meanNN, an
increase of SDNN, an increase of ASDNN and an in-
crease of pNN50 (Table 1). The values were asymmetric-
ally distributed at randomization baseline (Table 3).
Adjusted differences between randomized treatments
after 19 months were not significant (Table 4).
NT-pro-BNP values were within a low range at screen-
ing (see Additional file 1: Table S2A) and after 19
months of randomized treatment (Table 4). This also ap-
plies for values of the renin–angiotensin–aldosterone
system (RAAS) (Table 4, Additional file 1: Table S2A).
However, we observed significant adjusted differences
with an increase of noradrenalin and renin values in the
enalapril and metoprolol group (Table 4).
The KINDL total quality of life score did not deterior-
ate with time and showed no difference between treat-
ments at month 19 (Table 4). Pooled data for subscales
are visualized in the Additional file 1: Fig. S1A).
Results-safety/tolerability
After randomization, the majority of patients (33 of 38)
continued intake of study medication either up to the end
of the trial (14 versus 7, enalapril and metoprolol versus
placebo) or until the primary endpoint was reached (Fig.
2). In 2 versus 3 patients, intake terminated prematurely.
Reasons (multiple reasons could apply) included 5x
patient wish (2 versus 3), 3x withdrawal of consent (1 ver-
sus 2), 1x patient non-compliance (1 versus 0) and one ad-
verse event (0 versus 1: loss of appetite, increased feeling
of thirst). We noticed 13 protocol deviations: Adaptation
of dose level to increased body weight was delayed in 11
patients (4 enalapril and metoprolol, 7 placebo), not done
in one patient and prematurely done in another patient
(both enalapril and metoprolol). No unblinding occurred.
Adverse events (AEs) with onset after randomization and
the four weeks wash-out period of the placebo arm were re-
ported in 21/21 versus 15/16 (enalapril and metoprolol ver-
sus placebo) of the patients. Table 5 shows AEs that were
documented in more than one patient per arm. Incidence
of AE reports was 0.24 versus 0.26 per person-month on
study medication (enalapril and metoprolol: 181 AEs/739
person-months, placebo: 129 AEs/490 person-months).
The total number of patients with at least one serious AE
Table 2 Incidence of adverse events with onset from start of
run-in medication to 4 weeks after randomization (all patients)
Preferred term No. % 95% confidence intervals
Total number of patients 41 100%;
Patients with at least one AE 37 90% (77–97%)
Headache 11 27% (14–43%)
Nasopharyngitis 11 27% (14–43%)
Cough 8 20% (9–35%)
Nausea 8 20% (9–35%)
Febrile infection 6 15% (6–29%)
Diarrhoea 5 12% (4–26%)
Dizziness 4 10% (3–23%)
Fall 3 7% (2–20%)
Fatigue 3 7% (2–20%)
Pyrexia 3 7% (2–20%)
Abdominal pain 2 5% (0.6–17%)
Back pain 2 5% (0.6–17%)
Chest pain 2 5% (0.6–17%)
Decreased appetite 2 5% (0.6–17%)
Muscular weakness 2 5% (0.6–17%)
Rash 2 5% (0.6–17%)
Data are number of patients, percentage; 95% confidence interval
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(SAE) was 8/21 versus 7/16. None of the SAEs was clearly
related to verum or placebo medication. One patient in the
placebo-group stopped drug intake prematurely due to in-
creased hair loss (compare to hair loss, which led to with-
drawal in 1 patient during run-in-period).
Discussion
This randomized, double-blinded and placebo-controlled
trial investigated the effect of a combined ACE-inhibitor
and beta-blocker treatment on the progression to
DMD-related cardiomyopathy in boys with preserved
left ventricular function and between 10 and 14 years of
age. As the primary endpoint of this study, the time
from randomization to the first occurrence of LV-FS <
28% in the long-axis motion-mode of echocardiography
was chosen. The obtained results indicate a slower pro-
gression to left ventricular failure in DMD patients of
this age group receiving this combined pharamacological
intervention. Notably, the observed HR of 0.38 was even
more in favour of enalapril and metoprolol than antici-
pated at planning (0.46), and substantially more patients
were free of left-ventricular dysfunction for the first
three years (Fig. 2). However, these results did not reach
statistical significance, presumably due to the insufficient
sample size. After 3.5 years, the estimated rates of pa-
tients free of left-ventricular dysfunction in treated and
non-treated patients converged (Fig. 2). This might be a
random effect of the small remaining number of patients
Table 3 Baseline characteristics by randomized treatment (end of run-in therapy)
Enalapril and Metoprolol 1) Placebo 1)
Age [years] 12 ± 1.2 n = 21 11 ± 1.1 n = 17
Body Mass Index [kg/m2] 23 ± 6 n = 20 21 ± 5 n = 17
Ability to rise from supine position 24% 5/21 24% 4/17
Preserved ability to walk 33% 7/21 41% 5/17
Maximum walking distance [m] 200 (3–6000)2) n = 7 300 (30–800)2) n = 5
Systolic blood pressure [mmHg] 103 ± 16 n = 21 101 ± 11 n = 17
Patients with presence of cardiac symptoms 0% 0/21 0% 0/17
Steroid use or history of steroid use 76% 16/21 59% 10/17
NYHA class
Not applicable 52% 11/21 59% 10/17
NYHA class I 48% 10/21 35% 6/17
NYHA class II 0% 0/21 6% 1/17
Quality of life (KINDL total score at screening) 70.8 ± 10.1 n = 21 75.6 ± 10.0 n = 17
Echocardiography n = 21 n = 17
Left ventricle fractional shortening [%] 35 ± 3 36 ± 4
Electrocardiogram (ECG) n = 21 n = 17
Ventricular heart rate [beats/min] 84 ± 14 94 ± 16
Holter-Electrocardiogram (Holter-ECG) n = 20 n = 15
Ventricular heart rate [beats/min]
minimum 67 ± 12 72 ± 10
maximum 126 ± 17 133 ± 11
mean 90 ± 12 97 ± 9
Heart rate variability (Holter ECG) n = 11 n = 10
Mean NN [ms] 678 ± 80 571 ± 174
SDNN [ms] 98 ± 29 96 ± 30
SDANN [ms] 71 ± 24 75 ± 25
ASDNN [ms] 60 ± 20 54 ± 21
rMSSD [ms] 46 ± 26 45 ± 21
pNN50 [%] 17 ± 15 13 ± 11
1) Data are mean ± SD or percentage, n = number of measurements
2) Data are mean, (minimum-maximum), n = number of measurements
Demographic data were collected at screening, baseline data from echocardiography, ECG and Holter-ECG refer to measurements after
run-in/before randomization
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at risk after 3.5 years (5 vs. 4 patients, Fig. 2). The here
reported beneficial effects of enalapril and metoprolol
over placebo should be interpreted in view of the fact
that all patients started the study with medication of
enalapril and metoprolol in the run-in-period (Fig. 1),
which might have had a persistent effect in the placebo
group [18] and thus lowered the outcome differences be-
tween the two treatment groups.
Though direct comparison of our results with other
work addressing the effects of ACE-inhibitor and / or
beta-blockers treatment in the context of DMD cardiomy-
opathy are intrinsically hampered by differences in the in-
dividual study design (i.e. applied inclusion criteria for
case selection, specific medication, chosen diagnostic
workup), further studies support the notion of the here re-
ported beneficial effects. Mono-therapy with enalapril in a
2-year follow-up randomized trial with 21 patients with 42
DMD or BMD patients (mean age 12.1 years) with pre-
served left ventricular function was reported to decelerate
the progression of myocardial fibrosis as quantified by
CMR [21]. Eplerenone, an aldosterone antagonist, which
was used in combination with an ACE inhibitor or an
angiotensin receptor blocker, was reported to elicit a slight
deceleration of left ventricular circumferential strain de-
cline assessed by CMR in a 12month follow-up period in
20 DMD patients with preserved left ventricular function
(mean age 14.5 years). Here, the median decline of left
ventricular circumferential strain was 1% in the active
treatment group versus 2.2% in the placebo group [4]. The
aforementioned reduced decline of left ventricular circum-
ferential strain by eplerenone in combination with an
ACE inhibitor or an angiotensin receptor blocker treat-
ment was further confirmed in 11 DMD patients in a
2-years open-label extension trial [22]. Three further stud-
ies implicated that the use of ACE inhibitor or eplerenone
treatment may attenuate, but not prevent, the deterior-
ation of LV systolic function [4, 17, 21, 25, 26], which is
typically observed in DMD cardiomyopathy [4, 17, 21, 25,
26]. With regard to improvement of survival of DMD pa-
tients, two studies outlined positive effects by the early ini-
tiation of an ACE-inhibitor in patients with preserved left
ventricular function [17, 18]. Moreover, ACE-inhibitor
plus β-blocker treatment was reported to be more benefi-
cial in patients with asymptomatic compared to those with
symptomatic heart failure [27], and the combination ther-
apy with an ACE-inhibitor or angiotensin receptor blocker
plus β-blocker compared to mono-therapy was more fa-
vorable in DMD patients with abnormal left ventricular
ejection fraction [28].
In line with earlier studies [21, 22, 26], we observed a
relatively slow decline of global left ventricular function
in our series of DMD patients. Here, our analysis
showed that left ventricular fractional shortening de-
creased by − 0.10% per month in the enalapril and meto-
prolol group compared to − 0.13% per month in the
placebo group (95%CI − 0.25 to 0.00%, p = 0.042).
Fig. 2 Kaplan-Meier plot for time to left ventricular fractional shortening < 28%. Enalapril and metoprolol compared to placebo seemed to be in
favour for left ventricular shortening < 28% for the first three years (n.s.). After 3.5 years, the estimated rates of patients free of left-ventricular
dysfunction in treated and non-treated patients converged. Abbreviations: LVD = left ventricular dysfunction
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In our study up-titration of enalapril and metoprolol
without concealment was performed to test individual
tolerance of the guideline recommended high dosages
for anti-congestive indication [29]. The results of this
run-in period show that boys with DMD very well toler-
ate effective doses of medication with regard to blood
pressure, which in general is low in DMD patients. Drop
of blood pressure did not lead to withdrawals or adverse
event reporting in our series of patients. High heart rates
due to autonomous nerve system impairment have pre-
viously been reported in DMD patients [30–32] and
were also observed in the current study. During open
run-in treatment with ACE inhibitors and beta-blockers
we observed the expected effects on heart rate and ECG
and heart frequency variability [32]. However, these did
not show any obvious impact on left ventricular mea-
surements by echocardiography.
In the present study, special emphasis was further put
on the observation of safety, side effects and compliance
of the possibly life-long medication in patients, whose
quality of life already is severely hindered by severe mus-
cular dystrophy. While our analysis revealed a relatively
Table 4 Outcome at 19 months after randomization
Enalapril and Metoprolol Placebo Adjusted Difference 1)
Systolic blood pressure [mmHg] 104 ± 13 n = 19 108 ± 14 n = 14 −2.5 [−10.9 to 5.9] n = 38
Echocardiography
Left ventricle fractional shortening [%] 34 ± 3.9 n = 19 33 ± 5.7 n = 15 0.6 [−2.0 to 3.2] n = 38
Left ventricle diastolic diameter [cm] 4 ± 0.5 n = 19 4 ± 0.4 n = 15 0.1 [−0.2 to 0.4] n = 38
Interventricular septum systolic thickness [cm] 1 ± 0.2 n = 12 1 ± 0.5 n = 8 −0.1 [−1.5 to 1.3] n = 18
Electrocardiogram (ECG)
Ventricular heart rate [beats/min] 84 ± 16 n = 18 96 ± 12 n = 15 −4.8 [−12.5 to 2.9] n = 38
P-wave [ms] 84 ± 14 n = 18 73 ± 14 n = 15 10.3 [2.1 to 18.6]* n = 38
PQ-interval [ms] 129 ± 20 n = 18 115 ± 12 n = 15 10.9 [2.1 to 19.7]* n = 38
QRS-time [ms] 102 ± 67 n = 18 86 ± 9 n = 15 5.5 [−2.4 to 13.3] n = 38
QTc-time [ms] 405 ± 28 n = 18 415 ± 33 n = 15 −9.2 [−26.4 to 8.0] n = 38
Holter-Electrocardiogram (Holter-ECG)
Ventricular heart rate [beats/min]:
Minimum 68 ± 12 n = 15 75 ± 12 n = 14 −2.6 [−10.5 to 5.3] n = 32
Maximum 123 ± 14 n = 15 136 ± 15 n = 14 −16.7[−25.6 to −7.9]* n = 32
Mean 91 ± 13 n = 15 101 ± 14 n = 14 −5.2 [−12.8 to 2.3] n = 32
Heart rate variability (Holter ECG)
mean NN [ms] 681 ± 86 n = 8 650 ± 82 n = 6 −54.1 [− 160.2 to 52.0] n = 17
SDNN [ms] 85 ± 31 n = 9 90 ± 46 n = 7 −17.8 [−52.4 to 16.9] n = 18
SDANN [ms] 59 ± 29 n = 9 66 ± 36 n = 7 −19.0 [−47.4 to 9.4] n = 18
ASDNN [ms] 52 ± 18 n = 9 55 ± 33 n = 7 −13.0 [−37.5 to 11.6] n = 18
rMSSD [ms] 37 ± 15 n = 9 41 ± 32 n = 7 −12.9 [−40.2 to 14.3] n = 19
pNN50 [%] 12 ± 9 n = 9 13 ± 14 n = 7 −6.8 [−20.3 to 6.7] n = 18
Quality of life (KINDL total score) 2) 74.7 ± 12.3 n = 15 76.4 ± 6.4 n = 14 1.5 [−4.3 to 7.4] n = 36
Biomarker and neurohumoral markers 3)
NT-proBNP [pg/ml] 90 ± 69 n = 16 52 ± 42 n = 13 12 [− 13 to 38] n = 28
Noradrenalin [pg/ml] 355 ± 139 n = 12 188 ± 58 n = 9 124 [21 to 228]* n = 17
Renin [pg/ml] 297 ± 357 n = 16 38 ± 43 n = 12 332 [119 to 545]* n = 27
Aldosteron [ng/ml] 0.077 ± 0.097 n = 13 0.056 ± 0.036 n = 11 0.032 [−0.027 to 0.090] n = 24
Angiotensin II [pmol/ml] 19.4 ± 32.4 n = 16 15.6 ± 13.8 n = 12 −6.1 [−31.3 to 19.1] n = 27
Data are mean ± SD, n = number of measurements
* difference is statistically significant
1) Differences adjusted for baseline measurements after run-in; information from subjects with missing values at month 19 included in mixed model for
repeated measures
2) Differences adjusted for KINDL-questionnaire at screening; information from subjects with missing values at month 19 included in mixed model for
repeated measures
3) Measurements were taken at a mean of 19months (12.1 to 26.2 months). Differences adjusted for measurements at screening
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good compliance, neither meaningful differences of ad-
verse effects nor a negative impact on the quality of life
became apparent in the comparison between treatment
groups.
Conclusions
Our analysis of initiation of a combined therapy with
the ACE-inhibitor enalapril and the β-blocker metopro-
lol in DMD patients younger than 14 years of age and
with preserved left ventricular function is suggestive to
delay the progression of the intrinsic cardiomyopathy
to left ventricular failure. However, this delay did not
reach statistical significance, probably due to an insuffi-
cient sample size. In our patients long-term treatment
with this combination therapy was safe and well toler-
ated, and no negative impact on quality of life was seen.
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